Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-10 11:17 am Sale | 2025-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | Wellington Management Group LLP | 4,412,933 5.500% | -959,128 (-17.85%) | Filing History |
| 2026-01-08 09:09 am Purchase | 2025-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | FMR LLC | 8,928,574 11.200% | 3,048,963 (+51.86%) | Filing History |
| 2025-12-15 6:07 pm Purchase | 2025-12-11 | 13D | Kymera Therapeutics, Inc. KYMR | BIOTECHNOLOGY VALUE FUND L P | 6,867,809 8.500% | 1,036,638 (+17.78%) | Filing History |
| 2025-12-11 5:27 pm Purchase | 2025-12-09 | 13D | Kymera Therapeutics, Inc. KYMR | Baker Bros. Advisors LP | 8,676,797 10.900% | 2,010,257 (+30.15%) | Filing History |
| 2025-11-14 12:19 pm Sale | 2025-09-30 | 13G | Kymera Therapeutics, Inc. KYMR | T. Rowe Price Associates, Inc. | 5,097,704 7.100% | -1,547,770 (-23.29%) | Filing History |
| 2025-11-05 11:40 am Purchase | 2025-09-30 | 13G | Kymera Therapeutics, Inc. KYMR | FMR LLC | 5,879,611 8.200% | 1,470,377 (+33.35%) | Filing History |
| 2025-08-12 10:34 am Sale | 2025-06-30 | 13G | Kymera Therapeutics, Inc. KYMR | Wellington Management Group LLP | 5,372,061 7.700% | -624,812 (-10.42%) | Filing History |
| 2025-07-17 8:12 pm Purchase | 2025-06-30 | 13G | Kymera Therapeutics, Inc. KYMR | BlackRock Inc. BLK | 3,803,227 5.400% | 236,616 (+6.63%) | Filing History |
| 2025-06-30 8:26 pm Purchase | 2025-06-26 | 13D | Kymera Therapeutics, Inc. KYMR | Baker Bros. Advisors LP | 6,666,540 9.500% | 665,278 (+11.09%) | Filing History |
| 2025-05-12 10:44 am Purchase | 2025-03-31 | 13G | Kymera Therapeutics, Inc. KYMR | Wellington Management Group LLP | 5,996,873 9.200% | 689,547 (+12.99%) | Filing History |
| 2025-05-12 10:36 am Sale | 2025-03-31 | 13G | Kymera Therapeutics, Inc. KYMR | FMR LLC | 4,409,234 6.800% | -699,907 (-13.70%) | Filing History |
| 2025-04-30 11:12 am Purchase | 2025-03-31 | 13G | Kymera Therapeutics, Inc. KYMR | The Vanguard Group | 5,231,392 8.050% | 1,233,828 (+30.86%) | Filing History |
| 2025-02-10 10:25 am Purchase | 2024-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | Wellington Management Group LLP | 5,307,326 8.200% | 688,967 (+14.92%) | Filing History |
| 2024-11-14 4:31 pm Sale | 2024-09-30 | 13G | Kymera Therapeutics, Inc. KYMR | Atlas Venture Fund X L.P. | 4,173,216 6.400% | -794,898 (-16.00%) | Filing History |
| 2024-11-14 1:22 pm Purchase | 2024-09-30 | 13G | Kymera Therapeutics, Inc. KYMR | T. Rowe Price Associates, Inc. | 6,645,474 10.300% | 646,218 (+10.77%) | Filing History |
| 2024-11-14 09:30 am Purchase | 2024-09-30 | 13G | Kymera Therapeutics, Inc. KYMR | Avoro Capital Advisors LLC | 7,750,000 9.990% | 3,975,000 (+105.30%) | Filing History |
| 2024-11-12 10:32 am Purchase | 2024-11-08 | 13G | Kymera Therapeutics, Inc. KYMR | FMR LLC | 5,109,141 7.933% | 2,761,614 (+117.64%) | Filing History |
| 2024-11-08 10:52 am Sale | 2024-09-30 | 13G | Kymera Therapeutics, Inc. KYMR | Wellington Management Group LLP | 4,618,359 7.170% | -197,199 (-4.10%) | Filing History |
| 2024-08-22 4:15 pm Purchase | 2024-08-21 | 13D | Kymera Therapeutics, Inc. KYMR | Baker Bros. Advisors LP | 6,001,262 9.300% | 3,556 (+0.06%) | Filing History |
| 2024-04-01 08:57 am Purchase | 2024-03-28 | 13D | Kymera Therapeutics, Inc. KYMR | Baker Bros. Advisors LP | 5,997,706 9.800% | 1,778 (+0.03%) | Filing History |